Ductal Carcinoma in Situ disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: DCT002 MIFTS: 58	Ductal Carcinoma in Situ Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Ductal Carcinoma in Situ

MalaCards integrated aliases for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ ¹² ³⁰ ¹⁵ ¹⁷

Noninfiltrating Intraductal Carcinoma ⁷⁴

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:0060074

EFO ¹⁷ EFO_0000432

UMLS ⁷⁴ C0007124

Sources

Summaries for Ductal Carcinoma in Situ

Disease Ontology : ¹² A breast carcinoma in situ that is characterized by being non-invasive, not having spread outside of the duct into the surrounding breast tissue, has material basis in abnormally proliferating cells, derives from epithelial cells.

MalaCards based summary : Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to comedo carcinoma and in situ carcinoma. An important gene associated with Ductal Carcinoma in Situ is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Doxorubicin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and skin, and related phenotypes are Increased cell death HMECs cells and cellular

Wikipedia : ⁷⁷ Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

Sources

Related Diseases for Ductal Carcinoma in Situ

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 280)

#	Related Disease	Score	Top Affiliating Genes
1	comedo carcinoma	33.0	ERBB2 ESR1
2	in situ carcinoma	31.3	BRCA1 CDH1 EGFR ERBB2 ESR1 KRT14
3	breast reconstruction	31.2	BRCA1 BRCA2
4	gynecomastia	30.6	AR CYP19A1 ESR1 PGR
5	mammographic density	30.5	CYP19A1 ESR1 PGR
6	lobular neoplasia	30.3	BRCA1 CDH1 ERBB2 ESR1 MUC1
7	papillary carcinoma	30.2	CDH1 ERBB2 MUC1 PGR
8	breast fibroadenoma	30.1	CYP19A1 ERBB2 ESR1 KRT14 KRT8 PGR
9	bilateral breast cancer	30.1	BRCA1 BRCA2 ERBB2 PGR
10	papilloma	30.0	CCND1 KRT14 KRT5 KRT8 TP53
11	mammary paget's disease	29.9	EGFR ERBB2 ESR1 KRT8 MUC1 PGR
12	breast disease	29.6	BRCA1 BRCA2 CYP19A1 ERBB2 ESR1 KRT5
13	microglandular adenosis	29.5	EGFR ERBB2 PGR PIP TP53
14	breast ductal carcinoma	29.3	AR BRCA1 CCND1 CDH1 EGFR ERBB2
15	adenocarcinoma	29.1	AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
16	squamous cell carcinoma	28.7	AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
17	ovarian cancer	28.5	AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
18	breast cancer	26.7	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
19	breast apocrine carcinoma in situ	11.3
20	intracystic papillary adenoma	10.6	ERBB2 PGR
21	scirrhous adenocarcinoma	10.6	ERBB2 PGR
22	vestibular gland benign neoplasm	10.6	ESR1 PGR
23	vulvar benign neoplasm	10.6	ESR1 PGR
24	breast apocrine carcinoma	10.6	ERBB2 PGR
25	trigonitis	10.6	ESR1 PGR
26	vulvar syringoma	10.6	ESR1 PGR
27	lung leiomyoma	10.6	ESR1 PGR
28	vulvar leiomyoma	10.6	ESR1 PGR
29	bartholin's gland adenoma	10.6	ESR1 PGR
30	gastric papillary adenocarcinoma	10.6	ERBB2 TP53
31	endometrium carcinoma in situ	10.6	PGR TP53
32	breast intraductal proliferative lesion	10.5	EGFR ERBB2
33	rare adenocarcinoma of the breast	10.5	AKT1 TP53
34	breast papillomatosis	10.5	CCND1 ERBB2
35	brain ependymoma	10.5	EGFR TP53
36	protoplasmic astrocytoma	10.5	PTGS2 TP53
37	hereditary site-specific ovarian cancer syndrome	10.5	BRCA1 BRCA2
38	cerebral convexity meningioma	10.5	CDH1 TP53
39	mixed cell type cancer	10.5	ERBB2 PGR TP53
40	adenosarcoma	10.4	ESR1 PGR TP53
41	breast mucoepidermoid carcinoma	10.4	MUC1 PGR
42	supratentorial cancer	10.4	AKT1 EGFR TP53
43	central nervous system cancer	10.4	AKT1 EGFR TP53
44	cerebrum cancer	10.4	AKT1 EGFR TP53
45	glassy cell carcinoma of the cervix	10.4	ERBB2 ESR1 PGR
46	esophagus adenocarcinoma	10.4	ERBB2 PTGS2 TP53
47	barrett's adenocarcinoma	10.4	ERBB2 PTGS2 TP53
48	leukocyte disease	10.4	AKT1 CCND1 TP53
49	penile cancer	10.4	CCND1 EGFR TP53
50	malignant peritoneal mesothelioma	10.4	EGFR MUC1

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:

Sources

Symptoms & Phenotypes for Ductal Carcinoma in Situ

GenomeRNAi Phenotypes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased cell death HMECs cells	GR00103-A-0	9.1	BRCA1 EGFR PGR PIP S100A7 TP53

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

⁴⁷ (show all 26)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.49	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
2	growth/size/body region	MP:0005378	10.48	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
3	digestive/alimentary	MP:0005381	10.47	AR BRCA1 BRCA2 CCND1 CDH1 CYP19A1
4	cardiovascular system	MP:0005385	10.46	AKT1 AR BRCA1 CCND1 CDH1 CYP19A1
5	endocrine/exocrine gland	MP:0005379	10.46	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
6	homeostasis/metabolism	MP:0005376	10.46	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
7	hematopoietic system	MP:0005397	10.44	AKT1 AR BRCA1 BRCA2 CCND1 CLDN7
8	integument	MP:0010771	10.44	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
9	immune system	MP:0005387	10.42	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
10	behavior/neurological	MP:0005386	10.4	AKT1 AR BRCA1 BRCA2 CCND1 CYP19A1
11	mortality/aging	MP:0010768	10.4	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
12	embryo	MP:0005380	10.37	AKT1 AR BRCA1 BRCA2 CDH1 EGFR
13	adipose tissue	MP:0005375	10.28	AKT1 AR BRCA1 CYP19A1 EGFR ESR1
14	neoplasm	MP:0002006	10.27	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
15	limbs/digits/tail	MP:0005371	10.18	AR BRCA1 BRCA2 EGFR ERBB2 ESR1
16	muscle	MP:0005369	10.18	AKT1 AR BRCA1 CYP19A1 EGFR ERBB2
17	normal	MP:0002873	10.18	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
18	nervous system	MP:0003631	10.17	AKT1 AR BRCA1 BRCA2 CCND1 CYP19A1
19	craniofacial	MP:0005382	10.15	AR CCND1 EGFR ERBB2 KRT14 KRT5
20	liver/biliary system	MP:0005370	10.11	AKT1 AR CYP19A1 EGFR ESR1 KRT8
21	reproductive system	MP:0005389	10.06	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
22	no phenotypic analysis	MP:0003012	9.95	CDH1 EGFR ESR1 KRT5 PGR PTGS2
23	renal/urinary system	MP:0005367	9.86	AR BRCA1 CLDN7 CYP19A1 EGFR ESR1
24	pigmentation	MP:0001186	9.8	AR BRCA1 CYP19A1 EGFR KRT14 TP53
25	respiratory system	MP:0005388	9.61	AKT1 BRCA1 CCND1 EGFR ERBB2 ESR1
26	skeleton	MP:0005390	9.4	AKT1 AR BRCA1 BRCA2 CCND1 CYP19A1

Sources

Drugs & Therapeutics for Ductal Carcinoma in Situ

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Doxorubicin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

23214-92-8

31703

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2

50-18-0, 6055-19-2

2907

Docetaxel

Approved, Investigational

Phase 4,Phase 3,Phase 2

114977-28-5

148124

Epirubicin

Approved

Phase 4,Phase 3,Phase 2

56420-45-2

41867

Doxil

Approved June 1999

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

31703

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Topoisomerase Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antibiotics, Antitubercular

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2

Antineoplastic Agents, Alkylating

Phase 4,Phase 3,Phase 2

Antimitotic Agents

Phase 4,Phase 3,Phase 2,Phase 1

Alkylating Agents

Phase 4,Phase 3,Phase 2

Antirheumatic Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Immunologic Factors

Phase 4,Phase 3,Phase 2,Phase 1

Anastrozole

Approved, Investigational

Phase 3,Phase 2

120511-73-1

2187

Tamoxifen

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

10540-29-1

2733526

Sodium Citrate

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

68-04-2

Carboplatin

Approved

Phase 2, Phase 3,Phase 3

41575-94-4

10339178 38904 498142

Progesterone

Approved, Vet_approved

Phase 3,Phase 2,Not Applicable,Early Phase 1

57-83-0

5994

Cisplatin

Approved

Phase 2, Phase 3

15663-27-1

2767 441203 84093

mometasone furoate

Approved, Investigational, Vet_approved

Phase 3

83919-23-7

Medroxyprogesterone acetate

Approved, Investigational

Phase 3

71-58-9

leucovorin

Approved

Phase 3

58-05-9

143 6006

Fluorouracil

Approved

Phase 3,Phase 2

51-21-8

3385

Methotrexate

Approved

Phase 3

1959-05-2, 59-05-2

126941

Exemestane

Approved, Investigational

Phase 3,Phase 2

107868-30-4

60198

Bevacizumab

Approved, Investigational

Phase 3,Phase 2

216974-75-3

Letrozole

Approved, Investigational

Phase 3,Phase 2,Not Applicable

112809-51-5

3902

Leuprolide

Approved, Investigational

Phase 3

53714-56-0

657181 3911

Paclitaxel

Approved, Vet_approved

Phase 2, Phase 3,Phase 3,Phase 1

33069-62-4

36314

Capecitabine

Approved, Investigational

Phase 3,Phase 2

154361-50-9

60953

Trastuzumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

180288-69-1

9903

Pertuzumab

Approved

Phase 3,Phase 2,Phase 1

380610-27-5, 145040-37-5

2540

Sargramostim

Approved, Investigational

Phase 3,Phase 2,Phase 1

123774-72-1, 83869-56-1

Olaparib

Approved

Phase 2, Phase 3

763113-22-0

23725625

Metformin

Approved

Phase 3

657-24-9

14219 4091

Pembrolizumab

Approved

Phase 3,Early Phase 1

1374853-91-4

Oxybutynin

Approved, Investigational

Phase 3

5633-20-5

4634

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Adenosine

Approved, Investigational

Phase 3

58-61-7

60961

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

77-92-9

311

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Calcium

Approved, Nutraceutical

Phase 3,Phase 2,Phase 1,Not Applicable

7440-70-2

271

Lapatinib

Approved March 2007, Investigational

Phase 3,Phase 2,Not Applicable

231277-92-2, 388082-78-8

208908 9941095

Antineoplastic Agents, Hormonal

Phase 3,Phase 2,Phase 1,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Estrogen Receptor Antagonists

Phase 3,Phase 2,Phase 1,Not Applicable

Steroid Synthesis Inhibitors

Phase 3,Phase 2,Not Applicable

Citrate

Phase 3,Phase 2,Phase 1,Not Applicable

Selective Estrogen Receptor Modulators

Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 258)

#	Name	Status	NCT ID	Phase	Drugs
1	Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®	Completed	NCT01448447	Phase 4
2	Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer	Completed	NCT00742222	Phase 4
3	An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer	Completed	NCT01660542	Phase 4	Neoadjuvant Chemotherapy with Docetaxel
4	Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery	Recruiting	NCT02627248	Phase 4	Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
5	Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator	Unknown status	NCT00321048	Phase 3
6	Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer	Completed	NCT01112254	Phase 3
7	Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy	Completed	NCT00053898	Phase 3	anastrozole;tamoxifen citrate
8	Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions	Completed	NCT00262899	Phase 3
9	Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ	Completed	NCT00438659	Phase 3	mometasone furoate
10	Intraoperative Gamma Camera for Breast Cancer Surgery	Completed	NCT00757302	Phase 3
11	Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer	Completed	NCT00026286	Phase 3	conjugated estrogens;medroxyprogesterone
12	Study of Docetaxel in Breast Cancer Patients	Completed	NCT00174707	Phase 3	epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
13	S9630, Medroxyprogesterone in Treating Women With Breast Cancer	Completed	NCT00002920	Phase 3	medroxyprogesterone;tamoxifen citrate
14	Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer	Completed	NCT00374322	Phase 3	lapatinib
15	Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer	Completed	NCT00038467	Phase 3	Tamoxifen;Exemestane
16	Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane	Completed	NCT00036270	Phase 3	exemestane (Aromasin);tamoxifen + exemestane
17	BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer	Completed	NCT00528567	Phase 3	Bevacizumab;Standard adjuvant chemotherapy
18	Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer	Completed	NCT02980965	Phase 3	letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel;fluorouracil, epirubicin, cyclophosphamide, docetaxel
19	Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women	Completed	NCT00003906	Phase 3	Raloxifene;Tamoxifen
20	Management of Low-risk DCIS	Recruiting	NCT02492607	Phase 3
21	CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer	Recruiting	NCT02918084	Phase 3	Anastrozole or Letrozole or Exemestane;Anastrozole or Letrozole or Exemestane
22	Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer	Recruiting	NCT03150576	Phase 2, Phase 3	Olaparib;Paclitaxel and Carboplatin
23	Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer	Recruiting	NCT01905046	Phase 3	metformin hydrochloride
24	A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients	Recruiting	NCT03561740	Phase 3	capecitabine
25	Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy	Active, not recruiting	NCT00769379	Phase 3
26	Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS)	Active, not recruiting	NCT00907868	Phase 3
27	Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast	Active, not recruiting	NCT00470236	Phase 3
28	Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ	Active, not recruiting	NCT00072462	Phase 3	tamoxifen citrate;Anastrozole
29	Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ	Active, not recruiting	NCT00003857	Phase 3	tamoxifen citrate
30	APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer	Active, not recruiting	NCT00402519	Phase 3
31	Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia	Active, not recruiting	NCT01357772	Phase 3	Tamoxifen;placebo
32	Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients	Active, not recruiting	NCT02772731	Phase 3
33	A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer	Active, not recruiting	NCT01358877	Phase 3	5-Fluorouracil;Carboplatin;Cyclophosphamide;Docetaxel;Doxorubicin;Epirubicin;Paclitaxel;Pertuzumab;Placebo;Trastuzumab
34	Oxybutynin Chloride in Managing Hot Flashes	Active, not recruiting	NCT02961790	Phase 3	Oxybutynin Chloride
35	A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer	Active, not recruiting	NCT01566721	Phase 3	Herceptin
36	Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)	Active, not recruiting	NCT03036488	Phase 3	Carboplatin;Paclitaxel;Doxorubicin;Epirubicin;Cyclophosphamide;Placebo
37	Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer	Active, not recruiting	NCT00878709	Phase 3	neratinib
38	A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer	Active, not recruiting	NCT01966471	Phase 3	Trastuzumab Emtansine;Trastuzumab;Pertuzumab;Paclitaxel;Epirubicin;Doxorubicin;Docetaxel;Cyclophosphamide;5-Fluorouracil
39	Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer	Active, not recruiting	NCT01272037	Phase 3	Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
40	Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery	Active, not recruiting	NCT01349322	Phase 3
41	A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)	Active, not recruiting	NCT01772472	Phase 3	trastuzumab;trastuzumab emtansine
42	Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer	Enrolling by invitation	NCT03580395	Phase 2, Phase 3	Apatinib;paclitaxel;cisplatin
43	The LightPath® and 68Ga-RM2 in Breast Cancer Study	Not yet recruiting	NCT03731026	Phase 3	68Ga-RM2
44	Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS	Withdrawn	NCT00324714	Phase 3	risedronate sodium
45	Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)	Unknown status	NCT00669747	Phase 2	Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
46	Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole	Unknown status	NCT00077168	Phase 2	anastrozole;tamoxifen citrate
47	Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer	Unknown status	NCT01175694	Phase 2
48	Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland	Unknown status	NCT01630226	Phase 2	Neoadjuvant Cisplatin Chemotherapy
49	Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors	Unknown status	NCT01849250	Phase 2	Docosahexaenoic Acid
50	4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ	Completed	NCT00952731	Phase 2	oral placebo;afimoxifene;tamoxifen citrate;placebo gel

Search NIH Clinical Center for Ductal Carcinoma in Situ

Sources

Genetic Tests for Ductal Carcinoma in Situ

Genetic tests related to Ductal Carcinoma in Situ:

#	Genetic test	Affiliating Genes
1	Ductal Carcinoma in Situ ³⁰

Sources

Anatomical Context for Ductal Carcinoma in Situ

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

⁴²

Breast, Lymph Node, Skin, Prostate, Bone, Testes, Lung

Sources

Publications for Ductal Carcinoma in Situ

Articles related to Ductal Carcinoma in Situ:

(show top 50) (show all 2265)

#	Title	Authors	Year
1	Long-term Surveillance of Ductal Carcinoma in Situ Detected with Screening Mammography versus US: Factors Associated with Second Breast Cancer. ( 31038406 )	Choi SH...Park KW	2019
2	Breast Ductal Carcinoma in Situ: Precursor to Invasive Breast Cancer. ( 31029232 )	Coleman WB	2019
3	"Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data" by Hirth JM, Hatch SS, Lin Y, Giordano SH, Silva HC, Kuo Y. ( 30875106 )		2019
4	PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. ( 30844755 )	Agahozo MC...van Deurzen C	2019
5	Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study. ( 30738200 )	Lopez Gordo S...Seco Calvo J	2019
6	Parity Differently Affects the Breast Cancer Specific Survival from Ductal Carcinoma In Situ to Invasive Cancer: A Registry-Based Retrospective Study from Korea. ( 30728717 )	Lee J...Korean Breast Cancer Society	2019
7	Growth Dynamics of Mammographic Calcifications: Differentiating Ductal Carcinoma in Situ from Benign Breast Disease. ( 31112087 )	Grimm LJ...Ryser MD	2019
8	Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ. ( 30273605 )	Hannafon BN...Ding WQ	2019
9	Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ. ( 30385094 )	Sanati S	2019
10	Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. ( 30429518 )	Toss MS...Rakha EA	2019
11	Molecular Evaluation of Breast Ductal Carcinoma in Situ with Oncotype DX DCIS. ( 30605628 )	Nofech-Mozes S...Rakovitch E	2019
12	Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: Retrospective observational study. ( 30608397 )	Bertozzi S...Risaliti A	2019
13	Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. ( 30653209 )	Lehman CD...Comstock C	2019
14	MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ. ( 30659022 )	Guo Q...Miller WH	2019
15	Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma. ( 30712460 )	Song G...Feng G	2019
16	The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ. ( 30725481 )	Toss MS...Rakha EA	2019
17	miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway. ( 30989460 )	Lee J...Lee A	2019
18	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. ( 31065110 )	Miligy IM...Rakha EA	2019
19	A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. ( 31018242 )	Van Bockstal MR...van Deurzen CHM	2019
20	Survival Outcomes for Women with Ductal Carcinoma in Situ in the Era of Supplemental Screening. ( 31039074 )	Fowler AM	2019
21	Intraductal fulvestrant for Therapy of ERα-positive Ductal Carcinoma in Situ (DCIS) of the breast- a Preclinical Study. ( 31046118 )	Wang G...Sukumar S	2019
22	Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. ( 31060593 )	Petridis C...Sawyer EJ	2019
23	Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. ( 31089799 )	Goh CW...Zhu L	2019
24	The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice. ( 31092377 )	Montero-Luis A...Poortmans P	2019
25	Predictors of Invasive Breast Cancer in Patients With Ductal Carcinoma In Situ in Ultrasound-Guided Core Needle Biopsy. ( 30069893 )	Shin YJ...Lee SH	2019
26	Risk stratification of ductal carcinoma in situ using whole-lesion histogram analysis of the apparent diffusion coefficient. ( 30073498 )	Kim JY...Grimm R	2019
27	Discordant HER2 immunohistochemical expression and gene amplification in ductal carcinoma in situ - evaluating HER2 in synchronous in-situ and invasive carcinoma. ( 30117181 )	Hui Y...Wang Y	2019
28	Accuracy of Breast Magnetic Resonance Imaging Compared to Mammography in the Preoperative Detection and Measurement of Pure Ductal Carcinoma In Situ: A Retrospective Analysis. ( 30149976 )	Preibsch H...Wiesinger B	2019
29	Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS. ( 30190195 )	Paszat L...Rakovitch E	2019
30	Local Relapse After Breast-Conserving Therapy Versus Mastectomy for Extensive Pure Ductal Carcinoma In Situ ≥4 cm. ( 30253237 )	Hamilton SN...Truong P	2019
31	Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing. ( 30284611 )	Doebar SC...van Deurzen CHM	2019
32	Different Clinical and Pathologic Determinants Might be Possible to Predict Invasive Breast Cancer in Ductal Carcinoma In Situ in Ultrasound-Guided Core Needle Biopsy. ( 30298522 )	Altundag K	2019
33	Comparison of Clinical and Pathologic Characteristics of Ductal Carcinoma in Situ Detected on Mammography versus Ultrasound Only in Asymptomatic Patients. ( 30322671 )	Moon HJ...Park VY	2019
34	The decision to perform or omit sentinel lymph node biopsy during mastectomy for ductal carcinoma in situ should be tailored in accordance with preoperative findings. ( 30328007 )	Watanabe Y...Anan K	2019
35	Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. ( 30362065 )	Nakhlis F...King TA	2019
36	Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing. ( 30385093 )	Shee K...Tsongalis GJ	2019
37	Impact of pre-diagnosis depressive symptoms and health-related quality of life on treatment choice for ductal carcinoma in situ and stage I breast cancer in older women. ( 30406869 )	Buscariollo DL...Punglia RS	2019
38	In reply to Lambein et al.: 'HER2 protein overexpression in non-amplified ductal carcinoma in situ: quality issue or transcription mechanisms gone awry?' ( 30447011 )	Wang Y...Resnick MB	2019
39	Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. ( 30454971 )	Van Bockstal M...Floris G	2019
40	Evaluating the frequency of upgrade to malignancy following surgical excision of high-risk breast lesions and ductal carcinoma in situ identified by core needle biopsy. ( 30461129 )	Allen A...Smith B	2019
41	Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast. ( 30474777 )	Yonekura R...Akiyama F	2019
42	HER2 protein overexpression in non-amplified ductal carcinoma in situ: quality issue or transcription mechanisms gone awry? ( 30480328 )	Lambein K...Van Bockstal MR	2019
43	Leveraging the variable natural history of ductal carcinoma in situ (DCIS) to select optimal therapy. ( 30536119 )	Rojas KE...Borgen PI	2019
44	Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. ( 30539380 )	van Dooijeweert C...Deckers IAG	2019
45	Breast conserving surgery with targeted intraoperative radiotherapy for the management of ductal carcinoma in situ. ( 30589080 )	Banks A...Holmes DR	2019
46	No Ink on Ductal Carcinoma In Situ: A Single Centre Experience. ( 30591495 )	Fregatti P...Friedman D	2019
47	National consensus recommendations on patient-centered care for ductal carcinoma in situ. ( 30627960 )	Gagliardi AR...Warburton R	2019
48	BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. ( 30652428 )	Liu Y...Nakamura S	2019
49	Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score! ( 30665684 )	Marques LC...Andrade FEM	2019
50	Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. ( 30682163 )	Williams LA...Troester MA	2019

Sources

Genes for Ductal Carcinoma in Situ

Genes related to Ductal Carcinoma in Situ (0 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	29.86	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Expressions (show sections)
2	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	27.01	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	ESR1	Estrogen Receptor 1	Protein Coding	26.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	PGR	Progesterone Receptor	Protein Coding	26.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	TP53	Tumor Protein P53	Protein Coding	24.49	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	KRT5	Keratin 5	Protein Coding	23.97	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	KRT14	Keratin 14	Protein Coding	23.79	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	23.69	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	23.6	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	EGFR	Epidermal Growth Factor Receptor	Protein Coding	23.53	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	CCND1	Cyclin D1	Protein Coding	23.23	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	CDH1	Cadherin 1	Protein Coding	23.22	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	22.52	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	22.31	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	KRT8	Keratin 8	Protein Coding	22.08	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	AR	Androgen Receptor	Protein Coding	21.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	21.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	CLDN7	Claudin 7	Protein Coding	18.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Expressions (show sections)
19	S100A7	S100 Calcium Binding Protein A7	Protein Coding	13.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	PIP	Prolactin Induced Protein	Protein Coding	11.99	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Ductal Carcinoma in Situ

Cosmic variations for Ductal Carcinoma in Situ:

⁹ (show all 44)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location
1	COSM6005476	ZFHX3	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.2403A>T	p.K801N	16:72957743-72957743
2	COSM43559	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.517G>T	p.V173L	17:7675095-7675095
3	COSM10662	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.743G>A	p.R248Q	17:7674220-7674220
4	COSM10701	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.824G>T	p.C275F	17:7673796-7673796
5	COSM10656	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.742C>T	p.R248W	17:7674221-7674221
6	COSM10867	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.797G>A	p.G266E	17:7673823-7673823
7	COSM44415	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.711G>C	p.M237I	17:7674252-7674252
8	COSM44737	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.860A>G	p.E287G	17:7673760-7673760
9	COSM6932	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.733G>A	p.G245S	17:7674230-7674230
10	COSM10779	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.818G>T	p.R273L	17:7673802-7673802
11	COSM43714	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.836G>A	p.G279E	17:7673784-7673784
12	COSM44901	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.532C>G	p.H178D	17:7675080-7675080
13	COSM10660	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.818G>A	p.R273H	17:7673802-7673802
14	COSM43814	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.587G>C	p.R196P	17:7674944-7674944
15	COSM11089	TP53	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.584T>C	p.I195T	17:7674947-7674947
16	COSM6906973	SMARCA4	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.1111G>T	p.E371*	19:10987917-10987917
17	COSM6906974	PPP2R1A	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.510C>A	p.F170L	19:52212692-52212692
18	COSM12458	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.1634A>C	p.E545A	3:179218304-179218304
19	COSM775	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.3140A>G	p.H1047R	3:179234297-179234297
20	COSM776	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.3140A>T	p.H1047L	3:179234297-179234297
21	COSM760	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.1624G>A	p.E542K	3:179218294-179218294
22	COSM763	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.1633G>A	p.E545K	3:179218303-179218303
23	COSM774	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.3139C>T	p.H1047Y	3:179234296-179234296
24	COSM754	PIK3CA	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.1035T>A	p.N345K	3:179203765-179203765
25	COSM580	NRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.181C>A	p.Q61K	1:114713909-114713909
26	COSM565	NRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.35G>C	p.G12A	1:114716126-114716126
27	COSM6057047	NOTCH1	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.7372C>T	p.P2458S	9:136496367-136496367
28	COSM6005481	MAP2K2	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.931G>T	p.D311Y	19:4097332-4097332
29	COSM521	KRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.35G>A	p.G12D	12:25245350-25245350
30	COSM516	KRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.34G>T	p.G12C	12:25245351-25245351
31	COSM532	KRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.38G>A	p.G13D	12:25245347-25245347
32	COSM520	KRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.35G>T	p.G12V	12:25245350-25245350
33	COSM1179671	KMT2C	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.925C>T	p.P309S	7:152273792-152273792
34	COSM4595028	KMT2C	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.2681G>A	p.R894Q	7:152235905-152235905
35	COSM6057048	HRAS	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.148A>G	p.T50A	11:533908-533908
36	COSM6906971	H3F3A	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.218G>A	p.R73Q	1:226065745-226065745
37	COSM48358	ERBB2	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.929C>T	p.S310F	17:39711955-39711955
38	COSM14060	ERBB2	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.2264T>C	p.L755S	17:39723967-39723967
39	COSM19786	CDH1	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.779C>T	p.P260L	16:68810288-68810288
40	COSM6057049	AKT1	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.61A>G	p.T21A	14:104780202-104780202
41	COSM33765	AKT1	breast,NS,carcinoma in situ,ductal carcinoma in situ	c.49G>A	p.E17K	14:104780214-104780214
42	COSM5174142		breast,NS,carcinoma in situ,ductal carcinoma in situ	c.884C>T	p.S295F	17:39711955-39711955
43	COSM6906972		breast,NS,carcinoma in situ,ductal carcinoma in situ	c.1111G>T	p.E371*	19:10987917-10987917
44	COSM6964823		breast,NS,carcinoma in situ,ductal carcinoma in situ	c.659C>T	p.T220M	1:39897898-39897898

Sources

Expression for Ductal Carcinoma in Situ

Search GEO for disease gene expression data for Ductal Carcinoma in Situ.

Sources

Pathways for Ductal Carcinoma in Situ

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 69)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁵ Show member pathways ILK Signaling ⁶⁵ MAPK Signaling ⁶⁵ Molecular Mechanisms of Cancer ⁶⁵ Rho Family GTPases ⁶⁵	13.9	AKT1 BRCA1 CCND1 CDH1 EGFR ERBB2
2	GPCR Pathway ⁶⁵ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁵ Estrogen Pathway ⁶⁵ NFAT in Immune Response ⁶⁵ P2Y Receptor Signaling ⁶⁵ Pancreatic Adenocarcinoma ⁶⁵ Paxillin Interactions ⁶⁵ Ras Pathway ⁶⁵	13.76	AKT1 BRCA1 BRCA2 CCND1 EGFR ERBB2
3	Cytokine Signaling in Immune system ⁶⁷ Show member pathways Signaling by Interleukins ⁶⁷	13.39	AKT1 CCND1 EGFR ERBB2 MUC1 PTGS2
4	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	13.01	AKT1 BRCA1 CCND1 EGFR ERBB2 PTGS2
5	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.8	AKT1 AR BRCA2 CCND1 CDH1 EGFR
6	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁷ MET activates STAT3 ⁶⁷ Neurotrophin signaling pathway ³⁸ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.75	AKT1 CDH1 ERBB2 ESR1 PTGS2 TP53
7	Chks in Checkpoint Regulation ⁶⁵ Show member pathways DNA Repair Mechanisms ⁶⁵ Estrogen-mediated S-Phase Entry ⁶⁵ G2-M Phase Transition ⁶⁵ Parkinson's Disease Pathway ⁶⁵ SREBP Proteolysis ⁶⁵	12.73	BRCA1 BRCA2 CCND1 ESR1 TP53
8	ErbB signaling pathway ¹ ³⁸ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶² EGFR tyrosine kinase inhibitor resistance ³⁸ Renal cell carcinoma ³⁸ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.63	AKT1 CCND1 EGFR ERBB2 TP53
9	Pathways in cancer ³⁸	12.58	AKT1 AR BRCA2 CCND1 CDH1 EGFR
10	MicroRNAs in cancer ³⁸	12.51	BRCA1 CCND1 EGFR ERBB2 PTGS2 TP53
11	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.51	AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
12	WNT Signaling ⁶⁵	12.47	AKT1 CCND1 CDH1 PTGS2 TP53
13	Apoptosis Pathway ⁷³ Show member pathways Akt Pathway ⁷³ NF-kappaB Pathway ⁷³	12.46	AKT1 EGFR ERBB2 TP53
14	Development EGFR signaling pathway ²³ Show member pathways Development ERBB-family signaling ²³ EGF Pathway ⁶⁵ EGFR Signaling Pathway ⁶⁸ ErbB receptor signaling network ¹	12.46	AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
15	Development VEGF signaling via VEGFR2 - generic cascades ²³ Show member pathways Development VEGF signaling and activation ²³ VEGF - VEGF R2 Signaling Pathways ⁶⁶	12.43	AKT1 BRCA1 ESR1 PTGS2
16	Development Ligand-independent activation of ESR1 and ESR2 ²³ Show member pathways Transcription CREB pathway ²³ Transcription PPAR Pathway ²³	12.33	AKT1 CCND1 EGFR ERBB2 ESR1 PTGS2
17	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.32	AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
18	p53 Signaling ⁶⁵ Show member pathways p53 Pathway ⁶⁸	12.29	AKT1 BRCA1 CCND1 TP53
19	Cell cycle Role of SCF complex in cell cycle regulation ²³ Show member pathways Cell cycle ESR1 regulation of G1/S transition ²³ Cell cycle Regulation of G1/S transition (part 1) ²³ Immune response MIF-JAB1 signaling ²³	12.26	BRCA1 CCND1 ESR1 PGR
20	Proteoglycans in cancer ³⁸	12.26	AKT1 CCND1 EGFR ERBB2 ESR1 TP53
21	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁶ Show member pathways Akt Signaling Pathway ⁶⁶	12.23	AKT1 CCND1 EGFR ERBB2 TP53
22	AKT Signaling Pathway ⁶⁸	12.16	AKT1 CCND1 EGFR ERBB2 TP53
23	Transcription Androgen Receptor nuclear signaling ²³ Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²³	12.13	AKT1 AR CCND1 EGFR ERBB2
24	Signaling by PTK6 ⁶⁷ Show member pathways PTK6 Activates STAT3 ⁶⁷ PTK6 Down-Regulation ⁶⁷ PTK6 Expression ⁶⁷ PTK6 promotes HIF1A stabilization ⁶⁷ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁷ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁷ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁷ RAS signaling downstream of NF1 loss-of-function variants ⁶⁷	12.11	AKT1 CCND1 EGFR ERBB2
25	MAPK Pathway ⁷³ Show member pathways Toll-like Receptor Pathway ⁷³	12.08	AKT1 EGFR ERBB2 TP53
26	Spinal Cord Injury ¹	12.06	CCND1 EGFR PTGS2 TP53
27	Colorectal Cancer Metastasis ⁶⁵	12.06	AKT1 CCND1 CDH1 EGFR PTGS2 TP53
28	Cell cycle Cell cycle (generic schema) ²³ Show member pathways Cell cycle Regulation of G1/S transition (part 2) ²³ G0 and Early G1 ⁶⁷ G2 Phase ⁶⁷	12.03	AKT1 CCND1 CDH1 PTGS2 TP53
29	Thyroid hormone signaling pathway ³⁸	12.03	AKT1 CCND1 ESR1 TP53
30	DNA Damage Response (only ATM dependent) ¹	12.02	AKT1 CCND1 ERBB2 TP53
31	Glioblastoma Multiforme ⁶⁵	12	AKT1 CCND1 EGFR TP53
32	Interleukin-4 and 13 signaling ⁶⁷	12	AKT1 CCND1 MUC1 PTGS2 TP53
33	Signaling by ERBB4 ⁶⁷ Show member pathways Downregulation of ERBB4 signaling ⁶⁷ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁷	11.98	EGFR ERBB2 ESR1 PGR
34	Small cell lung cancer ³⁸	11.91	AKT1 CCND1 PTGS2 TP53
35	Nuclear Receptor transcription pathway ⁶⁷ Show member pathways Nuclear Receptors ¹	11.87	AR ESR1 PGR
36	Androgen receptor signaling pathway ¹	11.85	AKT1 AR BRCA1 CCND1 EGFR
37	Glucocorticoid receptor regulatory network ¹	11.84	AKT1 KRT14 KRT5 TP53
38	BRCA1 Pathway ⁶⁵ Show member pathways Fanconi's Anaemia Pathway ⁶⁵	11.83	BRCA1 BRCA2 TP53
39	Regulation of Wnt-mediated beta catenin signaling and target gene transcription ¹	11.81	AR CCND1 CDH1
40	Regulation of nuclear SMAD2/3 signaling ¹	11.79	AKT1 AR ESR1
41	Platinum drug resistance ³⁸	11.78	AKT1 BRCA1 ERBB2 TP53
42	Adherens junction ³⁸	11.76	CDH1 EGFR ERBB2
43	Transcription Ligand-dependent activation of the ESR1/SP pathway ²³ Show member pathways Development Ligand-dependent activation of the ESR1/AP-1 pathway ²³	11.75	CCND1 EGFR ESR1
44	Association Between Physico-Chemical Features and Toxicity Associated Pathways ¹	11.73	AKT1 EGFR ERBB2
45	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.73	AKT1 BRCA1 ERBB2 TP53
46	Regulation of Telomerase ¹	11.72	AKT1 CCND1 EGFR ESR1
47	Central carbon metabolism in cancer ³⁸	11.71	AKT1 EGFR ERBB2 TP53
48	IL-2 Gene Expression in Activated and Quiescent T-Cells ⁶⁵ Show member pathways TOB in T-Cell Signaling ⁶⁵	11.67	AKT1 CCND1 EGFR ERBB2
49	Validated targets of C-MYC transcriptional repression ¹	11.67	BRCA1 CCND1 ERBB2 S100A7
50	Bladder cancer ¹ ³⁸	11.67	CCND1 CDH1 EGFR ERBB2 TP53

Sources

GO Terms for Ductal Carcinoma in Situ

Cellular components related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:0005737	9.89	AKT1 AR BRCA1 BRCA2 CCND1 CDH1
2	nuclear chromatin	GO:0000790	9.56	AR ESR1 MUC1 TP53
3	protein-containing complex	GO:0032991	9.23	AKT1 AR BRCA1 BRCA2 EGFR ESR1
4	nucleus	GO:0005634	10.06	AKT1 AR BRCA1 BRCA2 CCND1 EGFR

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 37)

#	Name	GO ID	Score	Top Affiliating Genes
1	protein deubiquitination	GO:0016579	9.97	AR BRCA1 ESR1 TP53
2	positive regulation of protein phosphorylation	GO:0001934	9.9	AKT1 CCND1 EGFR ERBB2
3	cytokine-mediated signaling pathway	GO:0019221	9.89	AKT1 CCND1 MUC1 PTGS2 TP53
4	transcription initiation from RNA polymerase II promoter	GO:0006367	9.88	AR CCND1 ESR1 PGR
5	positive regulation of gene expression	GO:0010628	9.88	AKT1 AR BRCA1 ERBB2 PIP TP53
6	cell proliferation	GO:0008283	9.85	AKT1 AR BRCA2 EGFR ERBB2 TP53
7	positive regulation of peptidyl-serine phosphorylation	GO:0033138	9.84	AKT1 EGFR PTGS2
8	positive regulation of cell growth	GO:0030307	9.84	AKT1 EGFR ERBB2
9	cellular response to mechanical stimulus	GO:0071260	9.82	AKT1 EGFR PTGS2
10	response to estrogen	GO:0043627	9.81	BRCA1 CCND1 ESR1
11	cellular response to growth factor stimulus	GO:0071363	9.79	AKT1 EGFR ERBB2
12	positive regulation of smooth muscle cell proliferation	GO:0048661	9.78	AKT1 EGFR PTGS2
13	steroid hormone mediated signaling pathway	GO:0043401	9.76	AR ESR1 PGR
14	epidermis development	GO:0008544	9.76	EGFR KRT14 KRT5 S100A7
15	positive regulation of transcription, DNA-templated	GO:0045893	9.76	AKT1 AR BRCA1 BRCA2 CDH1 EGFR
16	cellular response to epidermal growth factor stimulus	GO:0071364	9.73	AKT1 EGFR ERBB2
17	response to organic substance	GO:0010033	9.73	AKT1 CCND1 CDH1 PTGS2
18	hemidesmosome assembly	GO:0031581	9.67	KRT14 KRT5
19	Leydig cell differentiation	GO:0033327	9.66	AR CCND1
20	positive regulation of RNA polymerase II transcriptional preinitiation complex assembly	GO:0045899	9.65	ESR1 TP53
21	positive regulation of vasoconstriction	GO:0045907	9.65	AKT1 EGFR PTGS2
22	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	9.64	EGFR TP53
23	mitotic G1 DNA damage checkpoint	GO:0031571	9.63	CCND1 TP53
24	prostate gland growth	GO:0060736	9.62	AR CYP19A1
25	negative regulation of ERBB signaling pathway	GO:1901185	9.59	EGFR ERBB2
26	cellular response to indole-3-methanol	GO:0071681	9.57	BRCA1 CDH1
27	response to estradiol	GO:0032355	9.56	CCND1 EGFR ESR1 PTGS2
28	chordate embryonic development	GO:0043009	9.55	BRCA1 BRCA2
29	morphogenesis of an epithelial fold	GO:0060571	9.54	AR EGFR
30	mammary gland development	GO:0030879	9.52	CYP19A1 PGR
31	tertiary branching involved in mammary gland duct morphogenesis	GO:0060748	9.51	AR PGR
32	mammary gland alveolus development	GO:0060749	9.5	AR CCND1 ESR1
33	positive regulation of transcription by RNA polymerase III	GO:0045945	9.35	AR
34	response to UV-A	GO:0070141	9.13	AKT1 CCND1 EGFR
35	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	8.92	BRCA1 BRCA2 MUC1 TP53
36	positive regulation of transcription by RNA polymerase II	GO:0045944	10.17	AKT1 AR BRCA1 EGFR ESR1 PGR
37	cellular response to DNA damage stimulus	GO:0006974	10.04	AKT1 BRCA1 BRCA2 CCND1 TP53

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	zinc ion binding	GO:0008270	9.95	AR BRCA1 ESR1 PGR S100A7 TP53
2	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	9.85	AR ESR1 MUC1 PGR TP53
3	protein kinase binding	GO:0019901	9.83	AKT1 CCND1 EGFR ESR1 TP53
4	beta-catenin binding	GO:0008013	9.7	AR CDH1 ESR1
5	protein phosphatase binding	GO:0019903	9.69	EGFR ERBB2 TP53
6	ATPase binding	GO:0051117	9.67	AR ESR1 PGR
7	identical protein binding	GO:0042802	9.65	AKT1 BRCA1 BRCA2 CDH1 CLDN7 EGFR
8	steroid hormone receptor activity	GO:0003707	9.58	AR ESR1 PGR
9	nuclear receptor activity	GO:0004879	9.54	AR ESR1 PGR
10	steroid binding	GO:0005496	9.5	AR ESR1 PGR
11	nitric-oxide synthase regulator activity	GO:0030235	9.33	AKT1 EGFR ESR1
12	enzyme binding	GO:0019899	9.28	AKT1 AR BRCA1 CCND1 EGFR ESR1
13	protein binding	GO:0005515	10.23	AKT1 AR BRCA1 BRCA2 CCND1 CDH1

Sources

Sources for Ductal Carcinoma in Situ

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia